High-performance thin layer chromatography, Iguratimod, Method validation, Stress degradation


Objective: The objective of the work was to develop and validate stability indicating HPTLC method for the estimation of Iguratimod.

Methods: The method employed HPTLC aluminium pre-covered silica gel 60 GF254 plates (10 cm × 10 cm with 250 μm layer thickness) as stationary phase while the solvent system was n-Hexane: Ethyl Acetate (5:5 v/v) with densitometric scanning at 256 nm. Sample was applied as a band of 8 mm width using Camag 100 μl sample syringe (Hamilton, Switzerland) using a linomat 5 applicator (Camag, Switzerland). Migration distance was 80 mm. Further the sample was subjected for stress conditions under acid and base hydrolysis, oxidation, thermal, neutral and photolytic conditions. Method validation done according to ICH Q2 (R1) guidelines.

Results: Retention factor (Rf) of the drug was 0.41±0.02. The linearity of the method was found to be within the concentration range of 200-1200 ng/band with R2= 0.983. Limit of detection and limit of quantification were found to be 34.69 and 105.12 ng/band respectively. The % mean recovery was found to be 100.38±0.83. Stress results showed that there is degradation in acid and base conditions but two degradant peaks were observed only under alkaline stress condition

Conclusion: The developed method found to be accurate, simple and precise. Method is successfully employed for quantification of the drug under various stress conditions.


Download data is not yet available.


Takano S, Yoshida C, Inaba T, Tanaka K, Takeno R, Nagaki H. 4H-1-benzopyran-4-one derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient. Toyama Chemical Company Ltd., Tokyo, Japan; 1990.

Damle MC, Ghode SP. Determination of Iguratimod in human plasma by HPLC method. World J Pharm Res. 2018 Oct;7(14):404-13.

Zhou T, Ding L, Li X, Zhang F, Zhang Q, Gong B. Determination of Iguratimod in rat plasma by high performance liquid chromatography: method and application. Biomed Chromatogr. 2008 Oct;22(3):260-4. doi: 10.1002/bmc.921, PMID 17939167.

Han JP, Zhu ZH, Wu YZ, Qian W, Li ZY, Nishikawa M. Preparation of a major metabolite of Iguratimod and simultaneous assay of Iguratimod and its metabolite by HPLC in rat plasma. Iran J Pharm Res. 2019;18(2):631-41. doi: 10.22037/ijpr.2019.1100641, PMID 31531047.

Xia Y, Zhao S, Gong M, Ding L. A rapid and sensitive LC–MS/MS method for analysis of Iguratimod in human plasma: application to a pharmacokinetic study in Chinese healthy volunteers. Biomed Chromatogr. 2018;32(9):e4277. doi: 10.1002/bmc.4277, PMID 29729125.

Kashid BB, More KR, Sharma B, Ghanwat AA. Identification, characterization and synthesis of Iguratimod process and degradation related impurities. World J Pharm Res. 2017 Oct;6(14):1212-21.

Nehete RB, Sharma P. Development and validation of HPLC method for the iguratimod. JOHR. 2018 Jan;6(1):1-8. doi: 10.30876/JOHR.6.1.2018.1-8.

Nehete RB, Sharma P. A study of method development and validation for quantification of Iguratimod in pharmaceutical dosage form by RP-HPLC method. J Emerg Technol Innov Res. 2018 Jan;5(1):141-50.

Nehete RB, Sharma P. Analytical method development and validation for related substance in Iguratimod by HPLC. J Emerg Technol Innov Res. 2018 Mar;5(3):151-7.

ICH guidelines for stability testing of new drug substances and products. Vol. Q1A (R2). Geneva, Switzerland; 2004. p. 1-24.

Ahmad S, Khabiya P, Au T, Raheman Bakhshi A. Quality by design approach to develop stability indicating reversed-phase high-performance liquid chromatography method development for ambroxol. Asian J Pharm Clin Res. 2021 Dec;14(12):44-9. doi: 10.22159/ajpcr.2021.v14i12.42939.

Katolkar P, Jaiswal S. Analytical method development and validation for the estimation of cyamemazine tartrate in formulation by RP-HPLC with stability indicating. Asian J Pharm Clin Res. 2022 Jun;15(9):28-32. doi: 10.22159/ajpcr.2022.v15i9.45154.

ICH guidelines for validation of analytical procedures: text and methodology. Vol. Q2(R1). Geneva, Switzerland; 2005. p. 1-17.

Rayudu S, Manoranjani M, Sekhara Reddy DR. Analytical method development and validation of dexmethylphenidate and serdexmethylphenidate by using RP-HPLC in bulk and pharmaceutical dosage form. Int J Appl Pharm. 2022 Mar;14(2):110-5. doi: 10.22159/ijap.2022v14i2.43515.

Sri KB, Shailaja GSV, Vallakeerthi N, Kumar VK, Sumakanth M. Development and validation of UV spectrophotometric method for simultaneous estimation of sitagliptin and metformin in bulk and combined pharmaceutical formulation. Int J Curr Pharm Sci. 2022 Mar;14(2):65-8. doi: 10.22159/ijcpr.2022v14i2.1963.



How to Cite

GANDHI, S. V., and M. JAGTAP. “DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPTLC METHOD FOR DETERMINATION OF IGURATIMOD IN BULK AND PHARMACEUTICAL DOSAGE FORM”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 14, no. 11, Nov. 2022, pp. 31-36, doi:10.22159/ijpps.2022v14i11.45705.



Original Article(s)